Merck to acquire Cidara Therapeutics for $9.2B. Cidara had a CCR5 asset in preclinical development that they halted due to financial constraints in order to focus on CD388. That asset is based on the same platform as CD388. I wonder if the CCR5 program will eventually be resurrected.

https://www.businesswire.com/news/home/202511...iral-Agent